Verano Holdings (VRNO) Capital Expenditures (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Capital Expenditures of $14.9 million for Q1 2026, up 7.74% year-over-year from $13.9 million in Q1 2025, and up 58.33% quarter-over-quarter from $9.4 million in Q4 2025.
Verano Holdings (VRNO) Capital Expenditures (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Capital Expenditures for 6 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 7.74% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $42.3 million (down 59.02% YoY), while the FY2025 annual figure was $41.2 million, down 58.38% from the prior year.
- Capital Expenditures grew to $14.9 million in Q1 2026 per VRNO's latest filing, from $9.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $106.4 million in Q3 2022 and bottomed at -$103.7 million in Q4 2022.
- Historically, Capital Expenditures has averaged $9.8 million across 5 years, with a median of $10.0 million in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 310.31% — and 2024, when it soared 468.04%.
- Verano Holdings' Capital Expenditures stood at -$103.7 million in 2022, then soared by 79.19% to -$21.6 million in 2023, then surged by 165.99% to $14.2 million in 2024, then tumbled by 33.77% to $9.4 million in 2025, then soared by 58.33% to $14.9 million in 2026.
- Business Quant data shows VRNO's Capital Expenditures at $14.9 million in Q1 2026, $9.4 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Verano Holdings | 433.71 Mn | 348.51 Mn | 99.70 Mn | 11.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.87 Mn |
| Jun 30, 2026 | 11.87 Mn |
| Mar 31, 2026 | 14.94 Mn |
| Mar 31, 2026 | 14.94 Mn |
| Dec 31, 2025 | 9.43 Mn |
| Dec 31, 2025 | 9.43 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 10.47 Mn |
| Jun 30, 2025 | 10.47 Mn |
| Mar 31, 2025 | 13.86 Mn |
| Mar 31, 2025 | 13.86 Mn |
| Dec 31, 2024 | 14.25 Mn |
| Dec 31, 2024 | 14.25 Mn |
| Sep 30, 2024 | 56.59 Mn |
| Sep 30, 2024 | 56.59 Mn |
| Jun 30, 2024 | 18.52 Mn |
| Jun 30, 2024 | 18.52 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Mar 31, 2024 | 9.70 Mn |